Research
Hormonal
Sotagliflozin is a dual SGLT1/SGLT2 inhibitor that reduces postprandial glycemia by blocking intestinal glucose absorption and renal glucose reabsorption.
Sotagliflozin is a newer diabetes medication that works in two places: your intestines and your kidneys. It helps lower blood sugar spikes after meals by preventing sugar absorption in the gut and removing sugar through urine. It is still being studied for long-term safety.
ModerateSupportsMEDIUM confidence
sotagliflozin (LX4211), acts by blocking small intestinal SGLT1 and renal SGLT2 and SGLT1... producing a diminished early phase on the absorption of glucose, reducing postprandial glycemia and insulin secretion
Why this rating
Described as under investigation with long-term studies needed.
Source
Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I
Raquel Vieira et al. · Pharmaceuticals · 2019
DOI 10.3390/ph12040152
narrative_reviewCited 184×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors lower blood glucose in Type 2 Diabetes by blocking renal glucose reabsorption, resulting in increased urinary glucose excretion without causing hypoglycemia.Good
- Metformin reduces fasting plasma glucose by inhibiting hepatic gluconeogenesis via AMPK activation and reducing free fatty acid plasma concentration.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →